ArticleFrontiers in pharmacology2025
Exploration of the role of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is one of the most common malignant tumors worldwide, with approximately one million people diagnosed with gastric cancer each year. Although the incidence and mortality rates of gastric cancer have decreased in recent years, it remains the third leading cause of cancer-related deaths globally. Methods: In this study, a network pharmacology approach was employed to identify relevant targets from drug and disease-related databases. The five active components of FOA were retrieved from the Swiss Target Prediction (http://www.swisstargetprediction.ch/) database, and 379 drug active component targets were predicted. A total of 14,092 gastric cancer targets were retrieved from the GeneCards (https://www.genecards.org/) database using the keyword "gastric cancer". Venny 2.1 was used to analyze the intersections, and a protein-protein interaction (PPI) network was constructed. The PPI network contains 328 nodes and 4,486 edges. Core targets were visualized and analyzed using Cytoscape software. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to elucidate the associated biological functions and signaling pathways. Meanwhile, molecular docking of core targets with the main chemical components of FOA was performed using AutoDock software. Finally, Results: Network pharmacology and molecular docking studies have shown that the triterpenic acid components in FOA exhibit strong molecular binding affinity with the core targets CASP3 and EGFR. They also predict that FOA may exert anti-gastric cancer effects by regulating pathways such as neuroactive ligand-receptor interaction and cancer-related pathways. Additionally, a method for extracting and purifying FOA triterpenic acids was successfully established, with its methodological validation meeting the required standards; chromatographic peaks of triterpenic acid indicator components were observed at the corresponding retention times (4.37 min, 16.71 min).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.